Lidds AB (FRA:5LD) Net Margin %: 0.00% (As of Sep. 2025)


What is Lidds AB Net Margin %?

Lidds AB FRA:5LD Net Margin % is 0.00% as of Sep. 2025. The stock has 2 warning signs investors should review.

Net margin is calculated as Net Income divided by its Revenue. Lidds AB's Net Income for the three months ended in Sep. 2025 was €-0.08 Mil. Lidds AB's Revenue for the three months ended in Sep. 2025 was €0.00 Mil. Therefore, Lidds AB's net margin for the quarter that ended in Sep. 2025 was 0.00%.

The historical rank and industry rank for Lidds AB's Net Margin % or its related term are showing as below:


FRA:5LD's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -89.33
* Ranked among companies with meaningful Net Margin % only.

Lidds AB  (FRA:5LD) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Lidds AB Net Margin % Related Terms

Lidds AB Net Margin % Historical Data

* Premium members only.

The historical data trend for Lidds AB's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lidds AB Net Margin % Chart

Lidds AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9,347.06 -1,048.84 -1,949.42 0.00 0.00

Lidds AB Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:5LD vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, Lidds AB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lidds AB Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lidds AB's Net Margin % distribution charts can be found below:

* The bar in red indicates where Lidds AB's Net Margin % falls into.


Lidds AB Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Lidds AB's Net Margin for the fiscal year that ended in Dec. 2024 is calculated as

Net Margin=Net Income (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-0.516/0
= %

Lidds AB's Net Margin for the quarter that ended in Sep. 2025 is calculated as

Net Margin=Net Income (Q: Sep. 2025 )/Revenue (Q: Sep. 2025 )
=-0.081/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Lidds AB (FRA:5LD) has a Net Margin % of 0.00% as of Sep. 2025. Net margin is the ratio of total net income to net sales. View historical data on Lidds AB and its competitors.
Is Lidds AB's Net Margin % too high?
Lidds AB's current Net Margin % is 0.00%.
How does Lidds AB's Net Margin % compare to VRTX and REGN?
Lidds AB's Net Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Lidds AB and its competitors. Lidds AB's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lidds AB stock overvalued right now?
Lidds AB (FRA:5LD) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Lidds AB (FRA:5LD), the current Net Margin % is 0.00% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lidds AB Business Description

Address c/o Excore, Kungsportsavenyen 22, Goteborg, SWE, 411 36
Lidds AB is a Sweden-based drug delivery company focused on its proprietary NanoZolid technology platform. The NanoZolid system is used to formulate drugs for local administration with controlled and sustained release over extended periods. The company offers this technology to partners and is also developing its own pipeline of drug candidates, prominently in oncology, where the platform is used to enable localized and sustained drug delivery. It has a pipeline with several projects in clinical development, both in early- and late-stage clinical phases, and projects about to enter clinical development.